Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Heron Therapeutics Inc.
DescriptionLong-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam in Heron's Biochronomer polymer-based drug delivery platform
Molecular Target Sodium channel voltage-dependent ; Cyclooxygenases (COX)
Mechanism of ActionCyclooxygenase (COX) inhibitor; Na channel blocker
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsPrevent post-operative pain following a bunionectomy; Prevent post-operative pain following unilateral open inguinal herniorrhaphy; Treat pain; Treat post-operative pain
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today